ACTIVE IMMUNITY OBTAINED BY PASSIVE IMMUNITY
Use of variable V from immunologically active protein (I.A.P.) molecules administered orally for immune system enhancement
Patrascu I.V., Chiurciu C.
Romvac has been conducting human and veterinary medicine research and production activities for over 50 years. It all started from the need for human and veterinary vaccines prepared on specific pathogen free (SPF) poultry. SPF poultry were used for the production of human and veterinary vaccines on embryonated eggs and on whole SPF embryo tissue cultures, for research and biological products control. Genetic studies were carried out at the SPF farms of Romvac regarding the role of sensitive and resistant allele in oncogenic virus-susceptible and -resistant SPF poultry. On this occasion, studies at Cornell University, Ithaca, NY. USA and Romvac demonstrated that in any genetic cross-combination the progenies with minimum one sensitivity allele are susceptible to developing the malign lymphoma called Marek’s Disease. It was proven to this extent that the sensitivity allele is dominant in any type of combination passed on to the progenies.
These activities were carried out in collaboration with specialists from Houghton Poultry Research Station, England and from Cornell University, Ithaca NY, USA.
Studies on oncogenic viruses were conducted at the same time on humans and animals, in collaboration with famous Romanian and American professors having constant support from the WHO. The activity in this field enabled us to discover in 1989 the greatest AIDS outbreak in children throughout the world, which ended in 1990 due to the first AIDS prevention and control program in Romania that was implemented together with the WHO.
Human and animal pathology studies expanded to the matter of antibiotic resistance for which we organized a similar research program that was different from that of other research institutes in the world.
Such studies were based on the active immunity produced in the body of animals and humans by oral administration of IAP. The immunologically active proteins (IAP) cross the digestive mucosa and reach the protein molecules that carry the V-variable, including lymphocytes B and T which they are directly effective against by transfer of target antigenic epitopes information. This information is absorbed differently by lymphocyte B and lymphocyte T respectively, each of these cells having distinct reactions. In the bone marrow, IgY is effective on the initial embryonic structures of lymphocyte B also by converting into …. and produces hyperactive lymphocytes B ten times more effective than the lymphocytes which have not reached IgY. The naïve lymphocyte T absorbs the negative information from the V-variable of IgY and transfers it to its own DNA which is to be cloned. This new mature lymphocyte reaches the hyperactive lymphocyte B where it transfers the negative information from the V-variable of IgY and stimulates idiotypic IgY-identical IgG production. The amount of antibodies produced in the animal organism corresponds to a vaccination with an attenuated live virus. This mechanism represents a part of the effects of immunomodulators and immunologically active proteins in the human organism.
The preclinical and clinical studies conducted during 2012-2016 revealed that we possess a set of immunologically active proteins (IAP) obtained on chickens (Gallus domesticus).
These products that have been prepared for the first time in the world are completely different from the biological products currently used for psoriasis treatment and for other immune disorders in humans as well.
- The biological products prepared on monoclonal antibodies or their protein structures are murine or human proteins considered as “non self” by the human organism, with adverse or idiotypic reactions against them. This group of products structured on mammalian molecules (mice, humans) is considered as “non self” in the human organism and induces multiple and violent adverse or idiotypic reactions that, within 10-14 days, reduce or even destroy these products in the human body. The parenteral administration of these products was shown to be inappropriate and harmful resulting in severe local and general reactions and even anaphylactic shock, which are life-threatening for people. Such products are to be replaced as soon as possible based on the recommendations from the European Food and Drug Administration, CDC Atlanta, Ge., ECDC Europe and from the scientific observations of certain specialists from EU, Japan, USA, Canada.
IAP are products obtained from poultry, that are phylogenetically 300 million years away from humans, more immunologically active than IgG of mammals, which are 35 million years away from humans. Under these conditions, the chicken reacts distinctly from mammals, including human being. Compared to monoclonal antibodies, IAPs are able to identify a large number of epitopes on the structure of the antigen and have specific effect against bacteria, viruses, fungi, unicellular parasites and even round worms. IAPs are specific and neutralize toxins, including exotoxins A and B caused by Clostridium difficile (Patrascu and co., unpublished data).
In the human body, IAPs are considered as “self” and induce no adverse or idiotypic reactions. Therefore, treatments have been carried out for 14 years on daily basis in humans, without adverse or idiotypic reactions throughout the treatment period.
Modern psoriasis treatment consists of biological drugs with a few deficiencies like blocking of certain cell functions and annihilation of parenterally administered cytokines, threatening the patient’s health due to some severe adverse and idiotypic reactions.
The emergence of antidrug antibodies (ADAS) against biological products resulted in functional or structural damage of biological products within 14-20 days post administration. ADAS may restrict the use of biological products for treatment of psoriasis, rheumatism and other diseases.
IAPs have a number of benefits compared to biological products, such as: interaction of V-variables, mucosal absorption, immunologically active proteins, big phylogenetic distance from humans, no adverse or idiotypic reactions, possibility of long-term treatment.
Preclinical research activities at ROMVAC were carried out at the same time with studies on treatment of antibiotic-resistant germ infections in humans, obtaining very good results in the treatment of urinary infections, prevention and treatment of nosocomial infections and treatment of respiratory tract infections.
PSORIASIS VULGARIS TREATMENT
Within the last two years we have started a treatment program for skin infections, on which occasion we found out that we could treat Psoriasis vulgaris using IAPs (more than 300 patients). Considering the properties of these proteins and the fact that for 14 years of study they have been accepted as “self” by the human body without inducing any adverse or idiotypic reactions, IAPs represent a scientific matter of particular importance. IAPs were used in children, resulting in healing of five of the 20 psoriasis children. The other children are still under treatment and their condition has improved. Another interesting fact of psoriasis children treatment is the wellbeing state that occurs in children and their parents as well. Preventive treatment is still administered in the cured children.
It has been for the first time in the world reported that the skin of patients who have been suffering from psoriasis for 30-55 years and cured, was completely healed without any scars. This is also an important matter to discuss in order to understand the changes occurring in the wounded skin and the way it heals.
IAPs must be administered without delay as well as the methods developed at ROMVAC for the treatment of all psoriasis children and for implementation of a special preventive program concerning potential psoriatic rashes in children, teenagers and adults.
EPIDERMOLYSIS BULLOSA (EB) IN CHILDREN
Upon request from a few parents with epidermolysis bullosa children, we administered an oral and topical IAP treatment in 4 children. These treatments are ongoing and we have not been able to determine a final assessment methodology or term yet.
It has been reported for the first time in the world that this disease of the digestive tube from mouth to anus can be successfully treated on short-term. At this moment we cannot know for sure what after-effects does EB cause in the digestive tube. After administering this IAP treatment, the internal and external wounds on the lips, oral and lingual mucosa, pharynx, esophagus, stomach and intestines have been healed and now children are able to eat normally and they can tolerate any kind of food, including cellulose-containing foods. These children now have a normal intestinal transit. Their health condition has significantly improved during this treatment.
At the same time, the respiratory tract and skin of 9-14 years old children born with EB have improved considerably. A 12 years old female patient with larynx wounds and changed voice, constantly coughing for 7 years and suffering from digestive disorders beginning with lips, tongue, palate, palatine velum and esophagus, received, under strict parental observation, IAPs by aerosols for the respiratory tract, orally for the general treatment and IAP solutions for topical skin treatment. Remarkable health status improvement was reported after 14 days with disappearance of cough, oral and esophageal wounds and normal voice. To this extent, the patient started eating normally and a state of wellbeing could be noticed both in the patient and her parents.
Significant improvement was recorded after 30 days, the skin on the soles healed and it became thicker, more flexible and resistant to trauma. During the following weeks, the patient reported that no more blisters had appeared on her skin.
The next step is the treatment and specialists will perform clinical examinations to describe each and every part of the body that has been affected by EB.
The small number of patients we have at present forces us to be scientifically cautious and circumspect. But we must make these results available since we are talking about the first children in the world suffering from EB, whose health condition has significantly improved. We are ready to provide information to all special medical institutions in Romania or other countries, and we can also present the entire treatment program including EB patients’ families.
The most important response is the digestive tube treatment result. A study carried out in Ireland on EB patients from more continents reported that both patients and caretakers wished to treat the digestive tube first and pain and skin wounds afterwards. (Maeve Jones-O’Connor, Dr. Amanda McCann, Avril. ATTITUDES TO CLINICAL RESEARCH WITHIN THE EPIDERMOLYSIS BULLOSA (EB) COMMUNITY. Student Medical Journal,2, 2015 Ireland)
Epidermolysis bullosa. Interface to an intense and applied scientific research
A meeting that should remain in the history of medicine regarding epidermolysis bullosa treatment.
The meeting took place in Iasi, on the 16th of September 2016 , during a Medical Conference, when two girls with epidermolysis bullosa came to visit us after having been treated with Romvac products and were feeling very well. We are reserved in saying the girls have healed, we want to make an international challenge regarding this matter. From now on, there should be a concern for epidermolysis bullosa (EB) regarding the terminology to be used for the EB patient who is clinically healed, physically and mentally recovered, as well as the mental recovery of the caretaker who in most cases is the mother. At the same time, the health care area of recovery and prevention (prevention of other episodes) should develop as far as epidermolysis bullosa concerns.
We should reconsider the definition of this disease which has been deemed incurable so far but it is not the case anymore as well as of the role of the genetic factor in susceptibility, onset and evolution of disease, at this moment when an immunological treatment with immunomodulators is successful in curing the clinical form and recover the mucosa and the skin. Consideration should be given the whole treatment which, besides the role of immunomodulators, also includes microbial infection treatment, standardized or personalized treatment .
Let’s leave for a second Dr. Lucia here in this picture, she is the one who takes care of the health of these children, and let’s take a look at this girl whom we have called EB2. You can see evidence of EB progress on her face and hands. She can talk and eat. There are deformed scars on her hands but she is now able to manage on her own and has become an active person. Moreover, to surprise us she told us that no more blisters had occurred on her skin and mucosa!
Within a few months, her life has changed radically in the good way. When she came to us on ….. she was a tender child who could not walk or talk and had a hoarse voice, the result of her coughing for 7 years then, she could not open her mouth because of the wounds, she could eat only powder milk or mashed food. She was like a hopeless hologram.
There was no hope for her or her family with respect to this disease, they could not find in the literature anything related to a cure or what to do and how to treat an EB patient.
Shortly after the beginning of treatment, i.e. days, her mother told us that she had started feeling better and her voice recovered from hoarseness, and that she had started eating and her digestion became normal. All this information came from a pharmacist, the girl’s mother, and since she was obviously working in the health care field, her information was of particular importance. Any news coming from this mother was highly significant. But it was more important to see her health status improvement, the medical, mental, physical and behavioral progress she had made.
Before leaving to Barcelona, a city now becoming a benchmark in medicine, I found out from EB2’s mother that her soles, which for 14 years had been covered by wounds and blisters, were healed. So she went away on holiday as a cured person. According to her, she walked until she developed muscle fever. She started eating anything and eventually she found out that she could also develop her personality and be energetic and emotional. When I said that she started eating anything, let’s not forget that for 14 years she had been eating mashed food and powder milk the most. She had to learn eating, chewing and swallowing all kinds of food. This happened in Barcelona where she did her best and won the battle! This family regained hope and wellbeing that we all wish for. What does the pharmacist mother say when she comes home from work in the evening and her daughter, after 14 years of pain, tells her that no more blisters have appeared and she is hungry.
It is not my intention to promote Spaniards or people from Barcelona but if someone wants their child free from EB then they have to come to us and thereafter go to Barcelona and learn how to walk and eat about everything, bread, fat pork, boiled corn etc.
If we talk about epidermolysis bullosa treatment, we should bring into discussion EB1 girl, the first to be cured from EB. I am very pleased to say that she is the first child in the world who has been successfully treated using ROMVAC products that contain active IAP principles and the results of which have been amazing. We use the pictures of this girl because the smile and optimism that she shows in all the materials will remain the symbol of this disease treatment. In this picture here she was caught eating candies, after having eaten an apple before. A few weeks back she had eaten grilled pork and boiled corn.
– What do I want to say?
– This girl has been cured from EB and her whole digestive tube is normal, she is a normal child. In order to eat boiled corn or bite from an apple, one must have normal lips, teeth, tongue, mouth and esophagus and these children can now ask for food and their mothers are happy to give them all they want. This moment is crucial for the EB patient and has been successfully achieved by IAP treatment. Let’s not forget a study carried out in Ireland by a group of specialists with funds from Debra Ireland. They found out that the first thing EB patients and their caretakers wanted was to cure (treat) the digestive tube and then to relieve the pain and cure the wounds (reference to the author). Our General Manager is unintentionally holding this girl’s hand and so we can see skin wounds that are about to heal and the right hand which is wrapped after a surgery separation of fingers, but progress is good. When we refer to EB1 and EB2 children we should not forget those we have to be thankful to, I am talking about ROMVAC research laboratory team. I am mentioning them all, lest someone should find us obsequious to our general manager!